- FDA fails to approve Mesoblast Steroid Refractory Pediatric Graft vs. Host Disease Stem Cell Therapy after FDA advisory board voted 9-1 recommending approval.
- FDA expresses concerns about Mesoblast MSC manufacturing process in its decision to request another placebo-controlled clinical trial.
- Mesoblast reveals it can only produce about 500 doses per bone marrow donation.
- Tiny Cynata Therapeutics has the answer to MSC scalability - unlimited doses from a single donor.
For further details see:
Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer